The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...

WuXi Biologics employees have once again exemplified their deep-rooted commitment to the local community, delivering ...

The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s ...

In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey ...

The Dundalk site was WuXi's first manufacturing investment in Europe and the company’s first investment of this scale outside ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...

China's WuXi Biologics has confirmed it will sell its vaccine facility in Ireland to US drugmaker Merck & Co for about €500 ...

WUXI Biologics Cayman will sell a vaccine facility in Ireland to Merck for about US$500 million as the Chinese company seeks ...

The pharmaceutical firm MSD is buying out the WuXi Vaccines manufacturing plant in Dundalk, in a €500m deal. The American ...

MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi ...